Physician

Anastasios Raptis

According to 2025 Medicare claims, Anastasios Raptis (NPI: 1962475509) practices hematology in the Pittsburgh, PA market, with the plurality of this provider's patient population coming from Allegheny, PA. This provider's primary affiliated billing organization is ONCOLOGY HEMATOLOGY ASSOCIATION INC (NPI: 1861469223; TIN: 251762980) and primary practice location at 15232-1301.

Raptis' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 249 traditional Medicare patients, billed 1,280 HCPCS/CPT codes, and received $91,466 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,599 prescription claims across 148 beneficiaries totaling $5,984,982 in drug costs, led by Pomalyst (Pomalidomide). 2021 DME data shows 81 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $53,335 to $91,466. Similarly, Part D prescription costs have risen steadily, from $496,751 to $5,984,982. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $255 to $879.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	155	816	$53,335
2016	179	827	$53,896
2017	199	908	$62,844
2018	231	1,008	$73,479
2019	245	868	$60,998
2020	250	1,061	$68,134
2021	257	940	$74,270
2022	264	1,108	$86,065
2023	254	1,018	$90,871
2024	249	1,280	$91,466

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	68	711	$496,751
2016	81	796	$860,270
2017	96	1,072	$2,010,434
2018	132	1,328	$3,230,469
2019	140	1,427	$4,365,972
2020	147	1,720	$5,364,537
2021	161	1,669	$5,033,219
2022	161	1,553	$4,848,779
2023	158	1,704	$4,425,168
2024	148	1,599	$5,984,982

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	22	$1,900
2017	N/R	22	$1,241
2018	N/R	24	$1,240
2019	N/R	12	$943
2020	N/R	N/R	N/R
2021	N/R	81	$540,633
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	121	427	$101
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	57	305	$89
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	78	108	$65
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	37	45	$41
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	107	305	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Pomalyst	Pomalidomide	52	1,456	$1,154,241
Jakafi	Ruxolitinib Phosphate	48	1,436	$813,463
Brukinsa	Zanubrutinib	49	1,470	$737,356
Lenalidomide	Lenalidomide	52	1,435	$722,107
Revlimid	Lenalidomide	41	1,057	$618,380

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Anastasios Raptis?

Tedicare shows public-source Medicare data for Anastasios Raptis (NPI 1962475509), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Anastasios Raptis have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Anastasios Raptis?

Anastasios Raptis is linked to ONCOLOGY HEMATOLOGY ASSOCIATION INC (billing NPI 1861469223) in the available physician profile data.

Does Anastasios Raptis have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.